• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Bayer opens Costa Rica plant for Essure device

Bayer opens Costa Rica plant for Essure device

August 28, 2015 By Brad Perriello

Bayer logoBayer (ETR:BAYN) yesterday cut the ribbon on a new plant in Costa Rica where it plans to make its Essure permanent contraception device.

The 15,000-square foot (1,400m) facility in Barreal de Heredia will initially add about 75 employees to Bayer’s 350-member workforce in Costa Rica, where the company has its Central American and Caribbean headquarters, according to the Costa Rican Investment Promotion Agency, CINDE. Bayer spent $12 million on the plant, according to the agency.

“We are proud that such a prominent international company like Bayer has decided to invest in our country to expand its operations in the manufacturing of medical devices which demonstrates its confidence in the Costa Rican human talent and our country,” Costa Rica President Luis Guillermo Solis said in prepared remarks.

Essure, the only permanent birth control device approved for the U.S. market, is a small metal coil placed in the fallopian tubes via catheter. The FDA approved the device in November 2002 under an expedited pre-market approval process; Bayer acquired the device in the $1.1 billion buyout of Conceptus in 2013.

Patients and a prominent activist struck up a hue and cry almost immediately after the Conceptus buyout, agitating for the device to be taken off the market and for Bayer to launch a complete investigation into patient injury claims. But in October 2013 the FDA said that real-world results don’t support reports of extreme fatigue, depression, weight-gain and other issues associated with the implant.

In February, a citizens petition lodged with the FDA asked wants the safety watchdog to take Essure permanent female sterilization device off the market, alleging that the clinical data the FDA used to approve the device was fudged and concealed adverse events associated with Essure. Bayer refutes the petition’s allegations, and in May cited results from a 5-year follow-up of the initial 364-patient cohort from its Phase III trial showing showed no pregnancies after 5 years and that the Essure inserts were “generally well tolerated.”

In June, the FDA scheduled a Sept. 24 advisory panel hearing on Essure, saying it’s received 5,093 complaints in the 13 years since Essure’s approval. There have also been 5 fetal deaths in women who became pregnant after using Essure and 4 adult deaths for reasons including infection and uterine perforation, according to the FDA. The device has been used by about 750,000 women, according to Bayer’s website.

Last month the FDA approved transvaginal ultrasound as an alternate test to confirm proper placement of the Essure device.

Filed Under: Women's Health Tagged With: Bayer

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy